(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Journey Travel Objections for Your Next Experience - 2Embrace Effortlessness: Moderation and Cleaning up Tips
- 3Scientists captured female sperm whales on video working together during a birth to protect the calf
- 4Air Force made critical errors during October 7 massacre, investigator says
- 5Astronomers spot white dwarf star creating a colorful shockwave
- Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- 6 US States for Fly Fishing
- US FDA investigates Takeda's blood disorder drug after pediatric death
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- Yemen's Houthis ready to join Iran war if needed, raising new shipping risk
- Email Promoting Instruments for Compelling Efforts
- In vogue Sleepwear Patterns for 2024
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Which Startup's Innovation Could Reform Medical care?
